Cancer Diagnostics

Gold standard milestone clears the path for national expansion of PanCystPro™ assay

Positive results from the RETAIN-2 trial demonstrate that a response-adapted bladder-preservation approach involving neoadjuvant chemoimmunotherapy can be considered in select patients

Identify the limitations of patient tissue controls in genetic testing and examine the verification data supporting cell line-derived standards

A review of cell line-derived reference standards for the investigation and molecular profiling of myeloid malignancies

The landscape of companion diagnostics is poised for transformative growth, driven by technological innovation, expanding therapeutic applications, and evolving regulatory support

High-throughput, automated EV processing from small blood samples could streamline multiplexed liquid biopsy workflows in clinical labs

CAP authors outline how genomic, transcriptomic, and epigenetic profiling can support pathologists when conventional histology and immunohistochemistry fall short, particularly in cancers of unknown primary

The test leverages cellular biophysics and machine learning to offer a high-sensitivity alternative to traditional urine-based assays

Roche’s PATHWAY HER2 (4B5) test is the only test approved to identify all levels of HER2 expression

More than 30 new drugs have been approved for pediatric cancer in the past 10 years, but progress has not benefited all patients